Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Genelux Corporation - Common Stock (NQ: GNLX )

2.690 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genelux Corporation - Common Stock

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END 
Via FinancialNewsMedia
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces New Chief Financial Officer
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces $18 Million Private Placement
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA)
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation Announces $33 Million Private Placement
From Genelux Corporation
Via GlobeNewswire
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
From Genelux Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.